Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea launches Zevtera in Germany
According to the European Centre for Disease Prevention and Control (ECDC), every year about 25,000 people die from antibiotic-resistant healthcare-associated infections in the EU. Basilea chief commercial officer
According to the European Centre for Disease Prevention and Control (ECDC), every year about 25,000 people die from antibiotic-resistant healthcare-associated infections in the EU. Basilea chief commercial officer
Astellas will regain all rights granted to Janssen after termination and the company is considering future plan for ASP015K outside Japan. The company will continue the phase III
The peptides are derived from a fragment of a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2). In vitro and in vivo studies showed the peptides’ ability
This is the first version of abacavir/lamivudine with scoring to allow for dose adjustment and is also flavored. The FDA’s tentative approval through the President’s Emergency Plan for
The grants will support researchers seeking to answer important questions about the virus’s fundamental nature, how it interacts with other substances, how it spreads, and how communication and
The acquired site, through its enhanced manufacturing capabilities, will help Johnson to meet increasing demand for custom pharmaceutical services and active ingredients. Johnson Matthey fine chemicals division director
GNbAC1 is said to be the first drug being developed to address a causal factor of the disease, and holds the potential to radically change the way MS
As part of an ongoing trial at the Jenner Institute at Oxford University, all the adult volunteers were earlier administered an experimental Ebola vaccine being developed by GSK
Novartis had been granted exclusive license in 2010, to develop and commercialize binimetinib. Designed specifically for cancer patients, the binimetinib is currently advancing in three Phase 3 clinical
Financial terms of the transaction were not disclosed by both the companies, however, sources familiar with the development have been cited by Reuters as saying that the deal